Bioventus BVS
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 65th percentile, 5-year average 32.7x
#1004 of 2991 stocks by PE (1 = cheapest)
Around its usual level · 59th percentile, 5-year average 2.6x
#3769 of 5329 stocks by PB (1 = cheapest)
Above its usual level · 75th percentile, 5-year average 1.0x
#1935 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.04 | – | 2.62 | 59% (pricier than usual) | #3769 of 5329 (1 = cheapest) |
| PE | 13.16 | 20.79 | 32.69 | 65% (pricier than usual) | #1004 of 2991 (1 = cheapest) |
| PS | 1.25 | 1.18 | 0.96 | 75% (pricier than usual) | #1935 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on BVS.
Sign in to join the discussion.